How can commercial pharma teams use technology to optimize launch activities? A majority – 85% – of industry executives say they expect to restructure their commercial models in the next few years. Teams need to know how to prioritize what should change, and how to make these changes without disrupting work in progress.

Life science companies can benefit from using social listening before, during, and after medical congresses to increase their understanding of the disease community landscape.

Life science companies have always been challenged to effectively develop, launch, and market new products in a competitive and fast-moving industry. Driving these decisions are expert insight from physicians, patients, payers, and internal stakeholders. But what if teams aren't talking to the right experts, or are engaging them ineffectively? And what happens if those insights aren't quickly used to inform strategy? This problem is known as the insight gap – a costly and risky problem that wastes time and money. In this paper, learn how to identify where the insight gap occurs, what causes it, and how to solve it.

Forward-thinking medtech team leaders will continue to rethink their strategies post-COVID. Those who take steps to innovate now will be positioned ahead of the pack.

Forward-thinking medtech team leaders will continue to rethink their strategies post-COVID. Those who take steps to innovate now will be positioned ahead of the pack.

Forward-thinking medtech team leaders will continue to rethink their strategies post-COVID. Those who take steps to innovate now will be positioned ahead of the pack.